Showing results (1-10 of 558) with videos related to
Sort By:
Pageof 56
Current Opinion in Rheumatology|March 25, 2020
Management of systemic sclerosis: the first five yearsDavid Roofeh, Dinesh KhannaCurrent Opinion in Rheumatology|March 20, 2021
Treatment for systemic sclerosis-associated interstitial lung diseaseDavid Roofeh, Alain Lescoat, Dinesh KhannaExpert Opinion on Emerging Drugs|October 15, 2020
Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trialsDavid Roofeh, Alain Lescoat, Dinesh KhannaCurrent Opinion in Rheumatology|March 15, 2019
Management of systemic sclerosis-associated interstitial lung diseaseDavid Roofeh, Sara Jaafar, Dharshan Vummidi, et al.Journal of Scleroderma and Related Disorders|April 6, 2022
Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trialsDavid Roofeh, Oliver Distler, Yannick Allanore, et al.Clinical Reviews in Allergy & Immunology|September 1, 2021
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate TherapiesAlain Lescoat, David Roofeh, Masataka Kuwana, et al.Clinical and Experimental Rheumatology|March 18, 2021
Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USAShobana Sankar, Mirette Habib, Sara Jaafar, et al.BMJ Open|March 12, 2021
Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocolAlain Lescoat, David Roofeh, Whitney Townsend, et al.Arthritis & Rheumatology (Hoboken, N.J.)|February 4, 2021
Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung DiseaseDavid Roofeh, Celia J F Lin, Jonathan Goldin, et al.Arthritis & Rheumatology (Hoboken, N.J.)|July 27, 2021
Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical PracticeDinesh Khanna, Alain Lescoat, David Roofeh, et al.Pageof 56